Latest content
- Pfizer announces phase 3 results for potential non-small cell lung cancer treatment
- MRM Health appoints Hans-Jürgen Wörle as Independent Director
- Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer
- MRM Health appoints Michel Detheux as Chairman of the Board
- Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses
Latest intelligence
- Bridging the gap between European brain innovation and real-world policy
- Obesity care in the UK – why it can’t improve until it is recognised as a disease
- The next frontier in clinical trials: navigating multi-disease research with GLP-1s
- Headline trade and market deals are opening doors to greater patient access
- Men’s health: the gap between awareness and action is where men’s lives are lost